-
Maximizing the Impact of In-Trial Interviews Through AI Assisted Analysis
Mar 10, 2025, 14:00 PM -
Exploring the Health and Well-being of Pediatric Caregivers within Chinese Cultural Contexts: A Systematic Review of Qualitative Studies from Chinese Databases
Mar 10, 2025, 14:00 PM -
Racial and Ethnic Disparities in Orphan Drug Utilization Among Medicare Beneficiaries
Mar 10, 2025, 14:00 PM -
Comparative Effectiveness of Novel vs Established Therapies in Obstructive Hypertrophic Cardiomyopathy (HOCM): Insights From a US Electronic Health Records (EHR) Study
Mar 10, 2025, 14:00 PM -
Real-World Evidence in FDA Approvals for Labeling Extension of Drugs and Biologics
Mar 10, 2025, 14:00 PM -
Da Vinci Robotic-Assisted Surgery: 5 years of Health Technology Assessment Trends and Recommendations
Mar 10, 2025, 14:00 PM -
Recent Evidence on the Comprehensive Burden of Pediatric Invasive Meningococcal Disease in the United States: A Systematic Literature Review
Mar 10, 2025, 14:00 PM -
Epidemiological and Economic Analysis of Hospitalizations for Cellulitis and Erysipelas From the Perspective of a Brazilian Health Insurance Company
Mar 10, 2025, 14:00 PM -
Content Validation of the Patient Attainment Scale-Essential Tremor (PAS-ET): A Novel Patient-Reported Outcome Measure Assessing Patient-Level Perceptions of the Importance, Current Function and Definitions of Meaningful Improvement in Tremor-Related...
Mar 10, 2025, 14:00 PM -
One Size Doesn’t Fit All: Learnings from a Pilot Survey Assessing Preferences for Improvement vs Worsening of Healthcare Professionals
Mar 10, 2025, 14:00 PM -
Integrating Cancer Trials Into Value-Based Care: The ‘Let Me Trial’ Model in Brazil
Mar 10, 2025, 14:00 PM -
Breaking Linguistic Barriers: Cross-Language HEOR & Evidence Integration Through GenAI
Mar 10, 2025, 14:00 PM -
Hepatitis C Elimination via Subscription-Based Payment Models: A Synthetic Control Study from Washington and Louisiana
Mar 10, 2025, 14:00 PM -
Gut Microbiota and Inflammation in Patients Which Schizophrenia
Mar 10, 2025, 14:00 PM -
Canada’s Evolving Market for Biosimilars and What It Means for Payers
Mar 10, 2025, 14:00 PM -
The Changing Impact of the Inflation Reduction Act on Payer Utilization Management- Insights from an Ongoing Quantitative Survey
Mar 10, 2025, 14:00 PM -
Modeling the Potential Public Health Impact and Cost-Effectiveness of BNT162b2 COVID-19 Adapted Booster Vaccination in Dominican Republic
Mar 10, 2025, 14:00 PM -
Healthcare Utilization and Costs in New Users of Once-Weekly GLP-1 Receptor Agonists vs Other Glucose-Lowering Therapies Among Medicare Beneficiaries With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease
Mar 10, 2025, 14:00 PM -
Characteristics of Patients Initiating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population
Mar 10, 2025, 14:00 PM -
Market Access as Defined by Professionals with Market Access Backgrounds - Scoping Review
Mar 10, 2025, 14:00 PM
